Microvascular function and inflammatory activation in Takotsubo cardiomyopathy.

Index of microvascular resistance (IMR) Inflammatory markers Takotsubo cardiomyopathy

Journal

ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191

Informations de publication

Date de publication:
Oct 2023
Historique:
revised: 14 05 2023
received: 23 02 2023
accepted: 21 06 2023
pubmed: 4 8 2023
medline: 4 8 2023
entrez: 4 8 2023
Statut: ppublish

Résumé

The aim of this study was to determine microvascular function in the acute phase of Takotsubo syndrome (TTS) and to identify inflammatory mediators that could reflect TTS-induced pathology. The study included 20 females [median age 65 years; interquarile range (IQR) = 58-70 years] with TTS according to the Mayo diagnostic criteria. During heart catheterization, we determined the index of microvascular resistance (IMR) and drew blood samples almost simultaneously from the aorta and coronary sinus. Cardiac magnetic resonance imaging (MRI) was done in the acute phase. We present descriptive coronary physiology and cardiac MRI data and compare inflammatory biomarkers between samples from the aorta, coronary sinus, and venous samples after 3 months using the Wilcoxon signed-rank test. For comparison, we also analysed the actual biomarkers in venous blood from 15 healthy female controls. A supplementary analysis explored Spearman's rank correlation between the inflammatory biomarkers, IMR, MRI data, and cardiac biomarkers. The median IMR was 16.5 mmHg·s (IQR = 10.5-28.2 mmHg·s), which was only slightly higher than that in the reference populations. Seven (35%) of the study subjects had IMR > 25 mmHg·s, suggesting a microvascular dysfunction. IMR was not affected by time from symptom onset. According to MRI, the apical region of the left ventricle was affected in 65% of the subjects. The median ejection fraction was 41% (IQR = 31-48%). Biomarker analyses revealed elevation of markers for extracellular matrix remodelling and fibrosis, inflammation, immune activation, and upstream inflammation as compared with healthy controls. Only the levels of interleukin (IL)-1 receptor antagonist and soluble T-cell immunoglobulin mucin domain-3 (sTIM-3) were higher in the coronary sinus than in the aorta. No variable was significantly correlated with IMR. The IL-6 level in the aorta was inversely correlated with the left ventricular ejection fraction. Growth differentiation factor-15, osteoprotegerin, and von Willebrand factor levels in both aorta and coronary sinus were positively correlated with N-terminal-pro-brain-natriuretic peptide, while the correlations of IL-6 and sTIM-3 with N-terminal-pro-brain-natriuretic peptide were restricted to the aorta and coronary sinus, respectively. While most of the markers were within normal limits after 3 months, matrix metalloproteinase-9 increased during follow-up to reach levels higher than those in the healthy controls. The median IMR was only slightly elevated in this study, but about one-third of the patients had values indicating microvascular dysfunction. The present study supports the involvement of several inflammatory pathways in TTS, including monocyte/macrophage activation, with sTIM-3 as a potential novel marker.

Identifiants

pubmed: 37537779
doi: 10.1002/ehf2.14461
pmc: PMC10567652
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3216-3222

Informations de copyright

© 2023 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

Références

Scand J Immunol. 2019 May;89(5):e12755
pubmed: 30729555
Eur Heart J. 2012 Sep;33(18):2290-6
pubmed: 22513778
Catheter Cardiovasc Interv. 2011 Jan 1;77(1):128-31
pubmed: 20506131
Atherosclerosis. 2012 Mar;221(1):254-9
pubmed: 22265272
Catheter Cardiovasc Interv. 2019 Nov 1;94(5):660-668
pubmed: 30790446
N Engl J Med. 2015 Sep 3;373(10):929-38
pubmed: 26332547
Eur Heart J. 2016 Apr 21;37(16):1325-33
pubmed: 26417057
Ann Intern Med. 2004 Dec 7;141(11):858-65
pubmed: 15583228
PLoS One. 2020 Apr 9;15(4):e0231202
pubmed: 32271823
JACC Basic Transl Sci. 2018 Dec 31;3(6):766-778
pubmed: 30623136
J Am Coll Cardiol. 2010 Jan 26;55(4):333-41
pubmed: 20117439
Circulation. 2019 Mar 26;139(13):1581-1592
pubmed: 30586731
Circ J. 2005 Aug;69(8):934-9
pubmed: 16041162
ESC Heart Fail. 2023 Oct;10(5):3216-3222
pubmed: 37537779
Eur Heart J. 2018 Jun 7;39(22):2032-2046
pubmed: 29850871
EuroIntervention. 2014 Jan 22;9(9):1069-75
pubmed: 24457279
Int J Cardiol. 2011 Dec 15;153(3):e51-3
pubmed: 21392831
J Am Coll Cardiol. 2018 Aug 21;72(8):874-882
pubmed: 30115226
Circ J. 2016;80(3):750-2
pubmed: 26794154
J Am Heart Assoc. 2019 Dec 17;8(24):e013701
pubmed: 31830875
Int J Cardiol. 2016 Apr 15;209:114-7
pubmed: 26889593
J Am Coll Cardiol. 2004 Nov 16;44(10):1970-6
pubmed: 15542278
Ann Med. 2009;41(6):462-70
pubmed: 19492201
BMJ Case Rep. 2019 Aug 28;12(8):
pubmed: 31466973
Int J Cardiol. 2017 Sep 1;242:31-32
pubmed: 28619334
Front Immunol. 2016 Jun 13;7:229
pubmed: 27379093
JAMA Cardiol. 2017 Jun 1;2(6):699-700
pubmed: 28273298
Int J Cardiol. 2014 May 15;173(3):424-9
pubmed: 24681016

Auteurs

Ole Geir Solberg (OG)

Department of Cardiology, Oslo University Hospital, Oslo, Norway.

Lars Aaberge (L)

Department of Cardiology, Oslo University Hospital, Oslo, Norway.

Gerhard Bosse (G)

Department of Radiology, Oslo University Hospital, Oslo, Norway.

Thor Ueland (T)

Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
K.G. Jebsen TREC, University of Tromsø, Tromsø, Norway.
Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital, Oslo, Norway.

Lars Gullestad (L)

Department of Cardiology, Oslo University Hospital, Oslo, Norway.
Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
K.G. Jebsen Cardiac Research Centre and Centre for Heart Failure Research, Faculty of Medicine, Oslo University Hospital, Oslo, Norway.

Pål Aukrust (P)

Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital, Oslo, Norway.
Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway.

Knut Stavem (K)

Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Department of Pulmonary Medicine, Akershus University Hospital, Lørenskog, Norway.
Department of Health Services Research, Akershus University Hospital, Lørenskog, Norway.

Classifications MeSH